{"brief_title": "Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer", "brief_summary": "To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.", "condition": ["Breast Neoplasms"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Tamoxifen", "Exemestane"], "description": ["Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.", "Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years."], "arm_group_label": ["B", "A"], "criteria": "Inclusion Criteria: - postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease Exclusion Criteria: - unresectable breast cancer - ER negative primary tumor", "gender": "Female", "minimum_age": "30 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Breast Neoplasms", "Exemestane", "Tamoxifen"], "id": "NCT00038467"}